You have read all your free articles, to continue reading subscribe to read the rest of this content.
Nordic Nanovector has enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab in 2nd-line follicular lymphoma (2L FL). The dosAlready a subscriber Login You have read all…
The company has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled studAlready a subscriber Login You have read all your…
The Clinical Trial Application (CTA) to initiate the company's Phase 2b study, with its candidate drug, AP1189, in patients with newly diagnosed rheumatoid arthritis (RA) has been approved in Moldova. The aim is to start recruitment of patients as soon as the study sites has been initiated in SepAlready a…
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patiAlready a subscriber Login…
